Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

NBTY CarbWise Low Carb Nutritional Line Slated For Summer Launch

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

NBTY will roll out a new line of low-carbohydrate products in July, when its CarbWise nutrition bar begins shipping to food, drug and mass outlets

You may also be interested in...



NBTY Shopping Has A Price As Charges Contribute To Earnings Drop

NBTY net earnings fell 46% to $15.9 mil. in the fourth quarter, pulled down by a $4 mil. charge relating to the aborted acquisition of Twinlab, the company said Nov. 10

NBTY Shopping Has A Price As Charges Contribute To Earnings Drop

NBTY net earnings fell 46% to $15.9 mil. in the fourth quarter, pulled down by a $4 mil. charge relating to the aborted acquisition of Twinlab, the company said Nov. 10

NBTY Shopping Has A Price As Charges Contribute To Earnings Drop

NBTY net earnings fell 46% to $15.9 mil. in the fourth quarter, pulled down by a $4 mil. charge relating to the aborted acquisition of Twinlab, the company said Nov. 10

Table

View full table

Related Content

HBW Insight
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS095400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By